Drugs Made In America Acquisition (DMAAR) Net Cash Flow (2025)

Drugs Made In America Acquisition (DMAAR) posted Net Cash Flow of $5420.0 for Q4 2025, up 5261.9% on a QoQ basis from -$105.0 in Q3 2025.

Drugs Made In America Acquisition (DMAAR) Net Cash Flow (2025) Analysis & Trends

Drugs Made In America Acquisition's Net Cash Flow history runs 1 years deep, the most recent figure standing at $5420.0 for Q4 2025.

Quarterly Net Cash Flow changed N/A year-over-year to $5420.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4786.0 (changed N/A YoY) and the FY2025 annual result came in at $4786.0, up 254.26% from the prior year.
Net Cash Flow was $5420.0 for Q4 2025 at Drugs Made In America Acquisition, up from -$105.0 in the prior quarter.
Across five years, Net Cash Flow topped out at $5420.0 in Q4 2025 and bottomed at -$428.0 in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Cash Flow (Qtr)
1	SIM Acquisition Corp. I	314.52 Mn	314.52 Mn	-	402,972.00
2	Thayer Ventures Acquisition	208.29 Mn	208.29 Mn	-	-260,081.00
3	Newbury Street II Acquisition	185.26 Mn	185.26 Mn	-	-275,113.00
4	Dynamix	178.78 Mn	178.78 Mn	-	-258,654.00
5	Hallmark Venture	103.01 Mn	102.76 Mn	-	-1,436.00
6	Voyager Acquisition	99.58 Mn	99.45 Mn	-	-
7	Gores Holdings X	95.80 Mn	95.37 Mn	-	-236,785.00
8	Archimedes Tech SPAC Partners	89.88 Mn	89.88 Mn	-	-46,350.00
9	Cohen Circle Acquisition	80.05 Mn	80.05 Mn	-	-396,098.00
10	Drugs Made In America Acquisition	1.46 Mn	1.46 Mn	-	5,420.00

Download Data